Market News AIOpen the app

Oppenheimer lowered its price target for Tvardi Therapeutics from $10 to $9 but still thinks it will do well.

OpinionRead the original at marketscreener.com
Neutral

Oppenheimer lowered its price target but kept its “Outperform” rating. The report gives mixed views of the shares and reports no change to Tvardi's business.

TVRD · Tvardi Therapeutics

AI read · Neutral

The AI's read

This reflects one firm's view of Tvardi's shares, not a reported change in the company's business. The lower target points in a negative direction, but Oppenheimer kept its positive “Outperform” rating. Those mixed signals do not support a clear change in Tvardi's outlook.

Get alerts for TVRD

Follow Tvardi Therapeutics (TVRD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for TVRD
Free on the App Store and Google Play, or on the web.